Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $45.02, but opened at $47.50. Zealand Pharma A/S shares last traded at $47.50, with a volume of 212 shares changing hands.

Analyst Ratings Changes

ZLDPF has been the topic of a number of recent research reports. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Wolfe Research cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Performance

The business has a 50 day moving average price of $45.47 and a 200 day moving average price of $50.21. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $3.40 billion, a P/E ratio of 3.52 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. The company had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. Analysts anticipate that Zealand Pharma A/S will post 2.37 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.